Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVA337 in diffuse cutaneous systemic sclerosis
NL-OMON45927Phase 2Recruiting
- Sponsor
- Inventiva
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanifibranor in systemic sclerosis (SSc) (3 arms), sponsored by Inventiva. Primary endpoint: Mean change in modified Rodnan Skin Score. Started Apr 2017; status: recruiting.
02
Drugs
lanifibranor
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON45927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45927.